Henrietta M Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2233901/publications.pdf

Version: 2024-02-01

279798 2,245 38 23 citations h-index papers

g-index 41 41 41 3994 docs citations times ranked citing authors all docs

395702

33

#	Article	IF	CITATIONS
1	Complement in the brain. Molecular Immunology, 2011, 48, 1592-1603.	2.2	345
2	Cerebrospinal fluid inflammatory markers in Parkinson's disease – Associations with depression, fatigue, and cognitive impairment. Brain, Behavior, and Immunity, 2013, 33, 183-189.	4.1	214
3	α-synuclein in the pathophysiology of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 23.	10.8	197
4	Astrocytic Aβ1â€42 uptake is determined by Aβâ€aggregation state and the presence of amyloidâ€associated proteins. Glia, 2010, 58, 1235-1246.	4.9	139
5	Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy. PLoS ONE, 2013, 8, e53250.	2.5	123
6	Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathologica, 2014, 127, 633-643.	7.7	120
7	Altered CSF Orexin and α-Synuclein Levels in Dementia Patients. Journal of Alzheimer's Disease, 2012, 29, 125-132.	2.6	90
8	Binding and uptake of Aβ1â€42 by primary human astrocytes <i>in vitro</i> . Glia, 2009, 57, 978-988.	4.9	86
9	The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. PLoS ONE, 2015, 10, e0135458.	2.5	85
10	The effect of amyloid associated proteins on the expression of genes involved in amyloid- \hat{l}^2 clearance by adult human astrocytes. Experimental Neurology, 2012, 233, 373-379.	4.1	81
11	Apolipoproteins E and J interfere with amyloidâ€beta uptake by primary human astrocytes and microglia <i>in vitro</i> . Glia, 2014, 62, 493-503.	4.9	71
12	Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiology of Disease, 2007, 26, 27-35.	4.4	69
13	Retinoic Acid Isomers Facilitate Apolipoprotein E Production and Lipidation in Astrocytes through the Retinoid X Receptor/Retinoic Acid Receptor Pathway. Journal of Biological Chemistry, 2014, 289, 11282-11292.	3.4	62
14	Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms. Journal of Proteome Research, 2014, 13, 1077-1087.	3.7	60
15	NG2 cells, a new trail for Alzheimer's disease mechanisms?. Acta Neuropathologica Communications, 2013, 1, 7.	5.2	50
16	Amyloidâ€beta 1â€40 is associated with alterations in NG2+ pericyte population exÂvivo and inÂvitro. Aging Cell, 2018, 17, e12728.	6.7	49
17	C4b-binding protein in Alzheimer's disease: Binding to AÎ 2 1â \in "42 and to dead cells. Molecular Immunology, 2008, 45, 3649-3660.	2.2	46
18	Apolipoprotein E lipoprotein particles inhibit amyloid- \hat{l}^2 uptake through cell surface heparan sulphate proteoglycan. Molecular Neurodegeneration, 2016, 11, 37.	10.8	45

#	Article	IF	Citations
19	The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 130.	5.2	44
20	Kynurenic Acid Levels in Cerebrospinal Fluid from Patients with Alzheimer's Disease or Dementia with Lewy Bodies. International Journal of Tryptophan Research, 2014, 7, IJTR.S13958.	2.3	36
21	Cell adhesion molecules in Alzheimer's disease. Degenerative Neurological and Neuromuscular Disease, 2012, 2, 65.	1.3	30
22	Peripheral apoE isoform levels in cognitively normal APOE $\hat{l}\mu 3/\hat{l}\mu 4$ individuals are associated with regional gray matter volume and cerebral glucose metabolism. Alzheimer's Research and Therapy, 2017, 9, 5.	6.2	29
23	Involvement of Matrix Metalloproteinase-9 in Amyloid-β 1–42–Induced Shedding of the Pericyte Proteoglycan NG2. Journal of Neuropathology and Experimental Neurology, 2014, 73, 684-692.	1.7	27
24	Brain integrity is altered by hepatic APOE $\hat{l}\mu4$ in humanized-liver mice. Molecular Psychiatry, 2022, 27, 3533-3543.	7.9	22
25	Associations Between APOE Variants, Tau and α-Synuclein. Advances in Experimental Medicine and Biology, 2019, 1184, 177-186.	1.6	19
26	Gender-Dependent Levels of Hyaluronic Acid in Cerebrospinal Fluid of Patients with Neurodegenerative Dementia. Current Alzheimer Research, 2012, 9, 257-266.	1.4	17
27	Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 9.	6.2	17
28	Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2014, 40, 343-350.	2.6	16
29	Multiple system atrophy and apolipoprotein E. Movement Disorders, 2018, 33, 647-650.	3.9	15
30	Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 71, 1217-1231.	2.6	14
31	Plasma Apolipoprotein E3 and Glucose Levels Are Associated in APOE É>3/É>4 Carriers. Journal of Alzheimer's Disease, 2021, 81, 339-354.	2.6	13
32	Effects of Alzheimer's peptide and $\hat{l}\pm 1$ -antichymotrypsin on astrocyte gene expression. Neurobiology of Aging, 2007, 28, 51-61.	3.1	11
33	O3-06-04: Apolipoprotein e affects neuronal alpha-synuclein uptake in an isoform-dependent manner., 2015, 11, P231-P231.		1
34	O2â€12â€06: NEUROPATHOLOGICAL FINDINGS DRIVEN BY AN APOEε4 LIVER PHENOTYPE. Alzheimer's and Dementia, 2018, 14, P652.	0.8	1
35	P4-024: APOLIPOPROTEIN E: AN UNEXPLORED MODULATOR OF CELLULAR ALPHA-SYNUCLEIN UPTAKE. , 2014, 10, P791-P792.		0
36	P1-096: IRAK-4 KINASE INHIBITION REDUCES PRO-INFLAMMATORY CYTOKINE SECRETION BUT HAS NO EFFECT ON THE UPTAKE OF AMYLOID BETA BY HUMAN GLIAL CELLS. , 2014, 10, P337-P337.		0

3

#	Article	IF	CITATIONS
37	P1-117: FIBRILLAR AMYLOID BETA 1-42 INCREASE YKL40 SECRETION FROM CULTURED PERICYTES. , 2014, 10, P343-P344.		0
38	Apolipoprotein E., 2013,, 7-23.		0